Peripheral blood indices to predict PFS/OS with anlotinib as a subsequent treatment in advanced small-cell lung cancer by Cuicui Zhang, Jing Wang, Xinyue Wang, Zhaoting Meng, Ying Cheng, Kai Li

Get full text

Durable efficacy of anlotinib in a patient with advanced thymic squamous cell carcinoma after multiline chemotherapy and apatinib: A case report and literature review by Ran Zuo, Cuicui Zhang, Li Lin, Zhaoting Meng, Yajie Wang, Yudong Su, Mihray Abudurazik, Ye Du, Peng Chen

Get full text

CD31‐labeled circulating endothelial cells as predictor in anlotinib‐treated non‐small‐cell lung cancer: Analysis on ALTER‐0303 study by Zhujun Liu, Jing Wang, Zhaoting Meng, Xinyue Wang, Cuicui Zhang, Tingting Qin, Jinliang Chen, Xiangli Jiang, Liuchun Wang, Li Lin, Xiaoling Zhang, Peng Chen, Chun Huang, Richeng Jiang, Kai Li

Get full text

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospecti... by Linlin Zhang, Liuchun Wang, Jingya Wang, Jinliang Chen, Zhaoting Meng, Zhujun Liu, Xiangli Jiang, Xinyue Wang, Chun Huang, Peng Chen, Yan Liang, Richeng Jiang, Jing Wang, Diansheng Zhong, Yanhong Shang, Yan Zhang, Cuiying Zhang, Dingzhi Huang

Get full text